Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
104 hedge funds and large institutions have $1.15B invested in Epizyme, Inc in 2017 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 48 increasing their positions, 24 reducing their positions, and 18 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 24
52% more call options, than puts
Call options by funds: $5.2M | Put options by funds: $3.42M
52% more capital invested
Capital invested by funds: $757M → $1.15B (+$393M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less funds holding
Funds holding: 108 → 104 (-4)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$68.6M |
| 2 |
Primecap Management
Pasadena,
California
|
+$26.4M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$18.5M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$14.1M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
CQS Cayman
Camana Bay, Grand Cayman,
Cayman Islands
|
-$9.28M |
| 2 |
CC
Casdin Capital
New York
|
-$7.85M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.9M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$2.27M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.78M |
EPZM Hedge Fund Activity: Q3 2017 in Review
104 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q3 2017, worth a combined $1.15B — up 52% from $757M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of EPZM and 14 opened new positions — a net loss of 4 holders — while 24 trimmed existing stakes and 48 added.
The largest buyer was Fidelity Investments, adding an estimated $68.6M. The largest seller was CQS Cayman, exiting entirely with an estimated $9.28M sold.
- 104 institutional investors held Epizyme, Inc (EPZM) as of Q3 2017, down from 108 in Q2 2017.
- Funds reported $1.15B of Epizyme, Inc stock for Q3 2017, up 52% quarter-over-quarter.
- 14 funds opened new Epizyme, Inc positions in Q3 2017 and 18 closed out, a net change of -4 holders.
- The largest Epizyme, Inc buyer in Q3 2017 was Fidelity Investments, an estimated $68.6M added.
- The largest Epizyme, Inc seller in Q3 2017 was CQS Cayman, an estimated $9.28M sold.
Based on aggregated 13F filings for Q3 2017.